Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Targets high-growth eye care expansion push
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Move comes amid rising regulatory pressures
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
